Desmopressin vs Mazdutide
Head-to-head comparison of Desmopressin (1-Deamino-8-D-arginine vasopressin) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Desmopressin | Mazdutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | 1-Deamino-8-D-arginine vasopressin | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | 1069.22 Da | ~5,000 Da |
| Half-Life | 1.5-3 hours | 5-7 days |
| Amino Acids | 9 | 37 |
| Typical Dose | 10-40 mcg intranasal | 1-6 mg weekly in obesity trials |
| Route | Intranasal/Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 35 | 28 |
| Research Status | Clinical | Clinical |
Desmopressin Benefits
- ✓memory consolidation
- ✓reduced pressor burden
- ✓recall support
- ✓short-term learning
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Desmopressin Dosing
intranasal research dosing|10-40 mcg or IU-equivalent studies|single-dose protocols
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Desmopressin Side Effects
- ⚠hyponatremia
- ⚠headache
- ⚠nasal irritation
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
Desmopressin
The literature is mixed, but desmopressin has shown memory-related effects in selected populations and experimental paradigms. Its cognitive effects are usually discussed as a vasopressin-pathway probe rather than a primary nootropic.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.